for co info. This co may have a lot going for it.
I'd like to add a little of this to my collection of
bios-pharmas. Couldn't find yet and wondering how much of split
or royalties Vertex is getting from sales of
Agenerase. And the protease inhibitor market at least for
hiv seems to be really almost getting flooded. But
like when I had Agouron unit their takeover. Their pro
inh really has good efficacy and one with the least
A recent article in Forbes described how Hoechst
is currently striving to transform itself into a
pure drug co. (selling off chemical assets, etc.) They
are also struggling to pump up their research
pipeline and strengthen their position in the
Considering this together with the recent deal, an eventual
takeover is not far fetched IMO...
The big spike up to near 35 a week before the
Hoechst Marion Roussel deal was announced, this last
wednesday, is now clearly not a takeover speculation spike,
as CNBC and other initially reported. It is pretty
clear to me that someone knew about this deal being
signed, and that a considerable abmount of insider
trading took place in advance of the announcement on
ought to be coming before too long. For example,
the hepatitis C trial of the IMPDH inhibitor was
begun a year ago. Was supposed to enroll 30 patients
with a 4-week evaluation.
Hello, Vrtx, care to
share your clinical findings with your loyal investors?